

Clarivate™

Sacituzumab tirumotecan significantly improves OS and PFS in endometrial carcinoma

Market Event Summary

Pragati Tripathi | May 2026

Pivotal global Phase 3 Trofuse-005 trial met all Primary endpoints

Background

- Treatment options for previously treated advanced or recurrent endometrial carcinoma are limited, with **chemotherapy being the standard of care amid rising first-line use of immune checkpoint inhibitors**.
- Sacituzumab tirumotecan (Sac-TMT), a **TROP-2 ADC, holds Commissioner's National Priority Voucher (CNPV)** in the United States and is already **approved** in **China** for **breast and non-small cell lung cancer.**
- Merck's **comprehensive TroFuse program** is advancing sac-TMT in **17 global Phase 3** trials across **multiple tumor types**.

Event

- The **registrational Phase 3 TroFuse-005** trial is evaluating Sac-TMT versus chemotherapy in **advanced or recurrent endometrial carcinoma** patients progressing on **platinum-based chemotherapy and anti-PD-1/PD-L1.**
- **Sac-TMT significantly improved OS and PFS** along with **ORR** (key secondary endpoint) in previously treated advanced or recurrent endometrial carcinoma. However, the results had not yet been disclosed at the time of writing.
- **Merck plans** to present **results** at an **upcoming medical meeting** and engage with **regulatory authorities across the globe.**

Clarivate's takeaways

Potential new standard-of-care

Sac-TMT is the first ADC to demonstrate a significant PFS and OS benefit, positioning it as a frontrunner to gain approval and reshape the treatment landscape of pre-treated endometrial carcinoma.

Broad applicability with commercial opportunity

The biomarker-independent profile of Sac-TMT expands commercial opportunity, differentiates it from other HER-2/B7-H4 ADCs, which can lead to wider adoption and stronger market impact. We expect Sac-TMT to be prescribed to roughly a quarter of second- and later-line drug-treated cases.

Intense competitive ADC late-phase pipeline

Late-phase ADC development is intensifying, with multiple agents progressing, including another TROP-2 ADC, sacituzumab govitecan. While Sac-TMT may have a first-mover advantage, its uptake will hinge on the magnitude of benefit, safety profile, and differentiation from other ADCs.

About the author

Pragati Tripathi, M.Pharm

Healthcare Research and Data Analyst

DRG Commercial Solutions

Prior to joining Clarivate, Ms. Tripathi was a senior research associate in the intellectual property and research division at Evalueserve in Gurgaon. She conducted secondary research and delivered technology landscape reports in the domain of pharmaceutical sciences and healthcare. She obtained her master's degree in pharmaceutical chemistry from the Birla Institute of Technology and Science in Pilani.

Clarivate coverage of endometrial carcinoma

- Endometrial carcinoma | Disease Landscape & Forecast | G7
- Advanced or Recurrent Endometrial Carcinoma | Unmet Need

Have a question?

lsh.support@clarivate.com
clarivate.com
+1 215 386 0100 (U.S.)
+44 (0) 20 7433 4000 (Europe)

About Clarivate

Clarivate is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit clarivate.com.